Department of Radiology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, China.
Department of Respiratory, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, China.
Curr Med Sci. 2022 Jun;42(3):561-568. doi: 10.1007/s11596-022-2539-y. Epub 2022 Jun 9.
To evaluate the impact of hypertension on the clinical outcome of COVID-19 patients aged 60 years old and older.
This single-center retrospective cohort study enrolled consecutive COVID-19 patients aged 60 years old and older, who were admitted to Liyuan Hospital from January 1, 2020 to April 25, 2020. All included patients were divided into two groups: hypertension and nonhypertension group. The baseline demographic characteristics, laboratory test results, chest computed tomography (CT) images and clinical outcomes were collected and analyzed. The prognostic value of hypertension was determined using binary logistic regression.
Among the 232 patients included in the analysis, 105 (45.3%) patients had comorbid hypertension. Compared to the nonhypertension group, patients in the hypertension group had higher neutrophil-to-lymphocyte ratios, red cell distribution widths, lactate dehydrogenase, high-sensitivity C-reactive protein, D-dimer and severity of lung lesion, and lower lymphocyte counts (all P<0.05). Furthermore, the hypertension group had a higher proportion of intensive care unit admissions [24 (22.9%) vs. 14 (11.0%), P=0.02) and deaths [16 (15.2%) vs. 3 (2.4%), P<0.001] and a significantly lower probability of survival (P<0.001) than the nonhypertension group. Hypertension (OR: 4.540, 95% CI: 1.203-17.129, P=0.026) was independently correlated with all-cause in-hospital death in elderly patients with COVID-19.
The elderly COVID-19 patients with hypertension tend to have worse conditions at baseline than those without hypertension. Hypertension may be an independent prognostic factor of poor clinical outcome in elderly COVID-19 patients.
评估高血压对 60 岁及以上 COVID-19 患者临床结局的影响。
本单中心回顾性队列研究纳入了 2020 年 1 月 1 日至 2020 年 4 月 25 日期间入住梨园医院的年龄在 60 岁及以上的连续 COVID-19 患者。所有纳入的患者分为两组:高血压组和非高血压组。收集并分析了患者的基本人口统计学特征、实验室检查结果、胸部计算机断层扫描(CT)图像和临床结局。使用二项逻辑回归确定高血压的预后价值。
在分析的 232 例患者中,105 例(45.3%)患者合并高血压。与非高血压组相比,高血压组患者的中性粒细胞与淋巴细胞比值、红细胞分布宽度、乳酸脱氢酶、高敏 C 反应蛋白、D-二聚体和肺部病变严重程度更高,而淋巴细胞计数更低(均 P<0.05)。此外,高血压组患者 ICU 入住率[24(22.9%)比 14(11.0%),P=0.02]和死亡率[16(15.2%)比 3(2.4%),P<0.001]更高,生存率显著更低(P<0.001)。高血压(OR:4.540,95%CI:1.203-17.129,P=0.026)与 COVID-19 老年患者的全因院内死亡独立相关。
COVID-19 老年患者中,高血压患者的基线病情较无高血压患者差。高血压可能是 COVID-19 老年患者临床结局不良的独立预后因素。